An Exploratory, Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder
Latest Information Update: 22 Feb 2024
At a glance
- Drugs Cannabidiol (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- Sponsors GW Research; Jazz Pharmaceuticals Inc
- 16 Feb 2024 Status changed from active, no longer recruiting to completed.
- 15 Dec 2023 This trial has been completed in Germany (Global end date: 19 Oct 2023).
- 22 Nov 2023 Planned End Date changed from 31 Oct 2023 to 22 Dec 2023.